Antivenom

Antivenom is a passive immunization biologic indicated for the emergency treatment of confirmed or strongly suspected venomous snakebite envenomation.

Established Use

• Treatment of systemic and/or significant local envenomation following the bite of a venomous snake, once envenomation is confirmed or strongly suspected based on clinical signs (e.g., spontaneous systemic bleeding, coagulopathy, neurotoxic signs, significant local swelling, cardiovascular instability) and, where possible, knowledge of the biting species.
• Antivenom should be selected, whenever possible, according to the specific snake species or venom type relevant to the geographic region, since antiserum is generally only effective against the venom(s) it was raised against (mono-, bi-, or polyvalent preparations).

Important Notes on Use

• Antivenom must be administered as soon as possible after a confirmed indication for treatment, in a hospital or emergency medical facility equipped and staffed to manage anaphylaxis, not in the field or as a substitute for first-aid transport.
• Not indicated for asymptomatic "dry bites" without evidence of envenomation; the decision to treat is based on clinical/laboratory evidence of envenomation per local snakebite management protocols, not on the bite alone.

Each vial of Snake Venom Antiserum contains purified, concentrated animal-derived (typically equine) immunoglobulins or immunoglobulin fragments (e.g., F(ab')2 or whole IgG) raised against the venom(s) of one or more medically important venomous snake species, together with a preservative and stabilizing excipients. It is generally supplied as a lyophilized powder or as a liquid concentrate for injection, with strength expressed in neutralizing units per vial rather than a simple milligram dose.

Refer to the manufacturer's product insert of the specific brand for exact venom-species coverage and unit potency.

Antivenom is a passive immunization biologic (antivenom/antivenin) prepared by immunizing animals, most commonly horses, with sub-lethal doses of one or more snake venoms and then purifying the resulting hyperimmune plasma to obtain venom-specific immunoglobulins or immunoglobulin fragments.

When administered to a person with venomous snakebite envenomation, these antibodies bind to and neutralize circulating venom toxins, helping to reverse or prevent the systemic and local effects of envenomation such as coagulopathy, neurotoxicity, and tissue damage. Antivenom is a hospital-only, physician-administered emergency treatment and is not an antibiotic.

Antivenom belongs to the therapeutic class of passive immunizing biologicals - specifically antivenoms/antivenins (immune sera) used for the neutralization of animal venom toxins.

Mechanism

Snake Venom Antiserum works by passive immunization: the animal-derived immunoglobulins or immunoglobulin fragments bind directly and specifically to snake venom toxins circulating in the blood and tissues, forming antigen-antibody complexes that neutralize the toxins' enzymatic and pharmacological activity (e.g., procoagulant, neurotoxic, myotoxic, or cytotoxic effects) and promote their clearance from the body.

Pharmacokinetics

Following intravenous administration, whole IgG or F(ab')2 fragment preparations of Snake Venom Antiserum distribute into the intravascular and extravascular space and are cleared over days; smaller Fab fragment preparations are cleared more rapidly and may be associated with venom/toxin "recurrence" requiring redosing. Clinical effect (e.g., restoration of normal coagulation, improvement of neurotoxic signs) is monitored clinically and with laboratory tests (e.g., whole blood clotting time) rather than by measuring antiserum levels.

Antivenom is given only by slow intravenous infusion in a hospital/emergency setting equipped for anaphylaxis management. See Dosage and Administration for full administration steps.

Clinically Significant Interactions

• Other biologic/protein-containing products or vaccines given concurrently: administering Antivenom together with other immunoglobulin-containing products may theoretically increase the overall risk or difficulty of attributing a hypersensitivity reaction; space administration and monitor closely when other biologics are clinically necessary.
• Anticoagulants/antiplatelet agents: in patients with venom-induced coagulopathy, concurrent anticoagulant or antiplatelet therapy can compound bleeding risk; these should generally be withheld until coagulopathy has resolved with Antivenom treatment, per physician judgment.
• Corticosteroids/antihistamines used for premedication or reaction treatment: these do not reduce the effectiveness of Antivenom and are commonly used adjuncts for managing or preventing hypersensitivity reactions; they should not be substituted for antiserum itself.

No well-established pharmacokinetic drug-drug interactions have been established for Antivenom; report all concurrent medications to the treating physician.

Early (Acute) Reactions

• Hypersensitivity reactions ranging from mild urticaria, itching, and flushing to severe anaphylaxis (hypotension, bronchospasm, angioedema, cardiovascular collapse) - most likely to occur during or shortly after infusion of Antivenom.
• Pyrogenic (fever, chills, rigors) reactions related to the protein load of the antiserum.
• Nausea, vomiting, and abdominal discomfort.

Delayed Reaction

• Serum sickness - a delayed hypersensitivity reaction typically occurring 5-14 days after administration of Antivenom, presenting with fever, urticaria, joint pain/swelling, lymphadenopathy, and malaise; usually managed with antihistamines and/or corticosteroids.

Any reaction during or after administration of Antivenom requires prompt medical evaluation.

Formal controlled studies of Antivenom in pregnancy and lactation have not been conducted. However, because untreated severe snakebite envenomation poses a serious, potentially fatal risk to both mother and fetus, Antivenom should not be withheld from a pregnant or breastfeeding woman with a clinical indication for treatment. It should be used only if clearly needed, with the potential benefit judged to outweigh the potential risk, and always under close physician supervision. Consult a physician for individualized guidance.

Hypersensitivity and Anaphylaxis

Antivenom is derived from animal (typically equine) serum and carries a meaningful risk of acute allergic reactions, including anaphylaxis, as well as delayed serum sickness (see Side Effects). It must only be administered in a facility equipped for anaphylaxis management, with epinephrine (adrenaline) and full resuscitation equipment immediately available, and by or under the supervision of a physician experienced in snakebite management.

Skin Testing

Skin testing prior to administration is not reliably predictive of hypersensitivity to Antivenom and is not routinely recommended in current guidance under many protocols; it should not delay treatment. Follow local/national snakebite management guidelines.

Time-Critical Treatment

Antivenom is a time-critical, physician-administered emergency treatment. Any suspected venomous snakebite requires immediate transport to a medical facility; do not delay seeking care, and do not rely on tourniquets, incision, suction, or other first-aid measures as a substitute for timely Antivenom treatment when it is indicated.

Dosing Basis

Dosing of Antivenom is based on clinical severity of envenomation, not patient weight, and must be directed by an experienced physician.

There is no well-defined "overdose" syndrome for Antivenom distinct from its known hypersensitivity risks, since dosing is titrated to clinical response under direct medical supervision; however, administering doses beyond what is clinically indicated increases the risk and severity of hypersensitivity reactions and serum sickness. Any suspected excessive or inappropriate administration of Antivenom, or any signs of a reaction (difficulty breathing, swelling, rash, dizziness, fever, joint pain), requires immediate medical attention; contact emergency services or a poison control center without delay. Do not attempt to manage such reactions at home.

Store Antivenom in a refrigerator at 2°C to 8°C; do not freeze. Protect from light. Keep out of reach of children. Discard any reconstituted/diluted solution not used within the time specified by the manufacturer. Always check the specific product's package insert, as storage conditions can vary slightly by brand and formulation.

Pregnancy and Lactation

See Pregnancy and Lactation - use only if clearly indicated, with benefit outweighing risk.

Pediatric Patients

Antivenom is used in children with confirmed or suspected envenomation using the same dose as adults for a given severity of envenomation (dosing is not weight-based); safety and efficacy considerations are the same as in adults, though children may be more susceptible to severe systemic envenomation and should be monitored especially closely.

Elderly Patients

No specific dose adjustment is established for elderly patients; the same clinical-severity-based dosing is used, with attention to comorbidities (e.g., cardiovascular disease) that may affect tolerance of infusion and any hypersensitivity reaction.

Renal/Hepatic Impairment

No specific dose adjustment of Antivenom is established for renal or hepatic impairment; dosing remains based on clinical severity of envenomation, with close monitoring given that venom-induced renal or hepatic injury may itself be part of the clinical picture requiring treatment.

Treatment with Antivenom continues until there is clear clinical and/or laboratory evidence that envenomation has been controlled (e.g., resolution of systemic bleeding, normalization of blood clotting tests, improvement of neurotoxic or cardiovascular signs), as judged by the treating physician. A single initial dose may be sufficient, or repeat doses may be required at intervals (e.g., every 1-2 hours or as protocol-directed) if envenomation signs persist or recur. There is no fixed standard duration; treatment is individualized and monitored in hospital.

Antivenom is commonly supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use. Reconstitute each vial with the volume of diluent supplied by the manufacturer (typically sterile water for injection or normal saline), gently swirling (do not shake vigorously) until the powder is fully dissolved and the solution is clear; do not use if the reconstituted solution is cloudy or contains particulate matter. The reconstituted Antivenom is then further diluted in an appropriate volume of intravenous fluid (e.g., normal saline) for slow intravenous infusion, per the product's package insert and institutional protocol. Use promptly after reconstitution.

Snake Venom Antiserum is classified as a biological product: an antivenom/antivenin (immune globulin/immune serum), within the broader category of passive immunizing agents.

Snake Venom Antiserum acts by providing pre-formed, venom-specific antibodies (or antibody fragments) that bind directly to circulating snake venom toxins, neutralizing their enzymatic and toxic activity and facilitating their clearance from the bloodstream, thereby halting or reversing the progression of local and systemic envenomation. This is passive immunization - Snake Venom Antiserum does not stimulate the patient's own immune system to produce antibodies, so protection is immediate but temporary.

Antivenom is used in pediatric patients with confirmed or strongly suspected venomous snakebite envenomation. The dose is the same as for adults for an equivalent degree of clinical envenomation severity - it is not calculated by body weight - because the goal is to neutralize a fixed venom load rather than to achieve a weight-based drug concentration. Children should be treated in a hospital setting with the same precautions for anaphylaxis and serum sickness as adults, and may require particularly close monitoring since envenomation can progress rapidly and severely in children. Safety and efficacy of Antivenom in children follow the same overall profile as in adults; formal pediatric clinical trials akin to those for standard drugs have not been conducted, as is typical for antivenom biologics used under emergency, lifesaving indications.